New hope for kids on dialysis: drug may stop deadly infections

NCT ID NCT06714864

First seen Sep 30, 2025 · Last updated May 09, 2026 · Updated 25 times

Summary

This study tests a drug called DefenCath to see if it can prevent serious bloodstream infections in children with kidney failure who need dialysis through a tube (catheter). About 36 kids from birth to 17 years old will take part. Half will get DefenCath and half will get the usual care, and researchers will compare how long it takes for an infection to happen.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CATHETER-RELATED INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's of Alabama/University of Alabama

    RECRUITING

    Birmingham, Alabama, 35233, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Cook Children's Health Care System

    RECRUITING

    Fort Worth, Texas, 76104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Nemours Children's Hospital - DE

    RECRUITING

    Wilmington, Delaware, 19803, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Stanford

    RECRUITING

    Palo Alto, California, 94304, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.